International Clinical Trial: Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518706) titled 'Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin' on April 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: HCC - Hepatocellular Carcinoma

Intervention: Drug: Tislelizumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 30, 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07518706

Published by HT ...